You are here: Industry Insights > ATH434

News List

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease prnasia
January 29, 2022
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases...
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial prnasia
December 15, 2021
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions...
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases prnasia
November 05, 2021
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions...
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program prnasia
October 20, 2021
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions...
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's prnasia
August 05, 2021
Alterity Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375.
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function prnasia
July 16, 2021
Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society ...
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial prnasia
June 24, 2021
Alterity Therapeutics Limited has received guidance from the European Medicines Agency (EMA) regarding key aspects of the Company's Phase 2 clinical trial for investigational drug ATH434 in the treatment of Multiple System Atrophy (MSA).
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials prnasia
February 10, 2021
Alterity Therapeutics has announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease (PD) based on imaging of brain iron.
Dr David Stamler Appointed CEO prnasia
January 08, 2021
The Board of Alterity Therapeutics is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases prnasia
November 17, 2020
Alterity Therapeutics has announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).

Previous page 1 2 Next page